148 related articles for article (PubMed ID: 33976743)
1. Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study.
Yeh CN; Hu CH; Wang SY; Wu CE; Chen JS; Tsai CY; Hsu JT; Yeh TS
J Cancer; 2021; 12(11):3335-3343. PubMed ID: 33976743
[No Abstract] [Full Text] [Related]
2. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.
Zhang X; Zhou Y; Wu X; Nie M; Zhang B; Zhou Y; Sun L; Liu Z; Liu X; Kou Y; Wang Y; Zhang Y; Hao C; Shen L; Li J
Eur J Surg Oncol; 2019 Mar; 45(3):318-323. PubMed ID: 30145000
[TBL] [Abstract][Full Text] [Related]
6. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
Raut CP; Wang Q; Manola J; Morgan JA; George S; Wagner AJ; Butrynski JE; Fletcher CD; Demetri GD; Bertagnolli MM
Ann Surg Oncol; 2010 Feb; 17(2):407-15. PubMed ID: 19898902
[TBL] [Abstract][Full Text] [Related]
8. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.
Call JW; Wang Y; Montoya D; Scherzer NJ; Heinrich MC
Clin Sarcoma Res; 2019; 9():4. PubMed ID: 30984366
[TBL] [Abstract][Full Text] [Related]
9. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
10. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
Vincenzi B; Nannini M; Badalamenti G; Grignani G; Fumagalli E; Gasperoni S; D'Ambrosio L; Incorvaia L; Stellato M; Spalato Ceruso M; Napolitano A; Valeri S; Santini D; Tonini G; Casali PG; Dei Tos AP; Pantaleo MA
Ther Adv Med Oncol; 2018; 10():1758835918794623. PubMed ID: 30181783
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study.
Hu CH; Yeh CN; Chen JS; Tsai CY; Wang SY; Cheng CT; Yeh TS
Oncol Lett; 2020 Sep; 20(3):2131-2142. PubMed ID: 32782530
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.
Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP
Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384
[TBL] [Abstract][Full Text] [Related]
13. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
14. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study.
Nannini M; Rizzo A; Nigro MC; Vincenzi B; Mazzocca A; Grignani G; Merlini A; D'Ambrosio L; Tolomeo F; Badalamenti G; Incorvaia L; Bonasera A; Fumagalli E; Miliziano D; Ligorio F; Brunello A; Chiusole B; Gasperoni S; Novelli M; Pantaleo MA
ESMO Open; 2021 Aug; 6(4):100222. PubMed ID: 34352702
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS; Laffi A; Gennaro N; Fazio R; D'Orazio F; Samà L; Siracusano LV; Sicoli F; Renne SL; Santoro A; Bertuzzi AF
Front Oncol; 2023; 13():1190123. PubMed ID: 37324004
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea.
Beom SH; Bae KB; Zang DY; Bae J; Hwang IG; Kang HJ; Woo IS; Shim BY; Bae BN; Cheon J; Oh SB; Ahn JB
J Cancer; 2022; 13(13):3396-3403. PubMed ID: 36313033
[No Abstract] [Full Text] [Related]
19. Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017.
Patterson T; Li H; Chai J; Debruyns A; Simmons C; Hart J; Pollock P; Holloway CL; Truong PT; Feng X
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326632
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
